1. Scrip

AstraZeneca's Gracell Acquisition Injects New Excitement For Cell Therapy In China

$1.2bn Validation Of Chinese Capabilities

 
• By Brian Yang

The UK drug maker’s latest deal marks the largest China biotech M&A deal to date, amid the lingering doom and gloom surrounding the fast emerging but cash-constrained sector.

arrow pointing to the year 2024 on a raised metal dial
AstraZeneca acquires Gracell Bio in validation of China cell therapy innovation • Source: Shutterstock

Just before Christmas, AstraZeneca delivered Santa's surprise to a sector in desperate need of new cash and a confidence booster.

The UK-based firm's 23 December announcement that it is to acquire China's Gracell Biotechnologies Co. Ltd. for up to $1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia